Overview

Long Term Administration Study of OPC-12759 Ophthalmic Suspension

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Rebamipide